Journal article
Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications
Diabetes (New York, N.Y.), Vol.54(1), pp.234-242
01/2005
DOI: 10.2337/diabetes.54.1.234
PMCID: PMC2756473
PMID: 15616034
Abstract
This study evaluated the effects of aldose reductase inhibition on diabetes-induced oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation. In animal experiments, control and streptozotocin-induced diabetic rats were treated with or without the aldose reductase inhibitor (ARI) fidarestat (16 mg · kg
−1
· day
−1
) for 6 weeks starting from induction of diabetes. Sorbitol pathway intermediate, but not glucose, accumulation in sciatic nerve and retina was completely prevented in diabetic rats treated with fidarestat. Sciatic motor nerve conduction velocity, hindlimb digital sensory nerve conduction velocity, and sciatic nerve concentrations of two major nonenzymatic antioxidants, glutathione and ascorbate, were reduced in diabetic versus control rats, and these changes were prevented in diabetic rats treated with fidarestat. Fidarestat prevented the diabetes-induced increase in nitrotyrosine (a marker of peroxynitrite-induced injury) and poly(ADP-ribose) immunoreactivities in sciatic nerve and retina. Fidarestat counteracted increased superoxide formation in aorta and epineurial vessels and in in vitro studies using hyperglycemia-exposed endothelial cells, and the DCF test/flow cytometry confirmed the endothelial origin of this phenomenon. Fidarestat did not cause direct inhibition of PARP activity in a cell-free system containing PARP and NAD
+
but did counteract high-glucose–induced PARP activation in Schwann cells. In conclusion, aldose reductase inhibition counteracts diabetes-induced nitrosative stress and PARP activation in sciatic nerve and retina. These findings reveal the new beneficial properties of fidarestat, thus further justifying the ongoing clinical trials of this specific, potent, and low-toxic ARI.
Details
- Title: Subtitle
- Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications
- Creators
- Irina G Obrosova - Department of Internal Medicine, University of Michigan, Ann Arbor, MichiganPal Pacher - Laboratory of Physiological Studies, National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism, Bethesda, MarylandCsaba Szabó - Inotek Pharmaceuticals, Beverly, MassachusettsZsuzsanna Zsengeller - Inotek Pharmaceuticals, Beverly, MassachusettsHiroko Hirooka - Drug Development Research Laboratories, Sanwa Kagaku Kenkyusho, Mie, JapanMartin J Stevens - Department of Internal Medicine, University of Michigan, Ann Arbor, MichiganMark A Yorek - Veterans Affairs Medical Center and Department of Internal Medicine, University of Iowa, Iowa City, Iowa
- Resource Type
- Journal article
- Publication Details
- Diabetes (New York, N.Y.), Vol.54(1), pp.234-242
- DOI
- 10.2337/diabetes.54.1.234
- PMID
- 15616034
- PMCID
- PMC2756473
- ISSN
- 0012-1797
- eISSN
- 1939-327X
- Language
- English
- Date published
- 01/2005
- Academic Unit
- Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984094483702771
Metrics
35 Record Views